References
- Walker PO. Huntington's disease. Lancet 2007; 369: 218–28. Neurological Research.
- Fan MM, Raymond LA. N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog Neurobiol 2007; 81: 272–93.
- Ali NJ, Levine MS. Changes in expression of N-methyl-D-aspartate receptor subunits occur early in the R6/2 mouse model of Huntington's disease. Dev Neurosci 2006; 28: 230–8.
- Heng MY, Detloff PJ, Wang PL, Tsien JZ, Albin RL. In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. J Neurosci 2009; 29: 3200–5.
- Centonze D, Prosperetti C, Barone I, Rossi S, Picconi B, Tscherter A, et al. NR2B-containing NMDA receptors promote the neurotoxic effects of 3-nitropropionic acid but not of rotenone in the striatum. Exp Neurol 2006; 202: 470–9.
- Arning L, Kraus PH, Valentin S, Saft C, Andrich J, Epplen JT. NR2A and NR2B receptor gene variations modify age at onset in Huntington disease. Neurogenetics 2005; 6: 25–8.
- Fantin M, Marti M, Auberson YP, Morari M. NR2A and NR2B subunit containing NMDA receptors differentially regulate striatal output pathways. J Neurochem 2007; 103: 2200-11.
- Fantin M, Auberson YP, Moran i M. Differential effect of NR2A and NR2B subunit selective NMDA receptor antagonists on striato-pallidal neurons: relationship to motor response in the 6-hydroxydopamine model of parkinsonism. J Neurochem 2008; 106: 957–68.
- Femagut PO, Diguet E, Stefanova N, Biran M, Wenning GK, Canioni P, et al. Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57BL/6 mice: behavioural and histopathological characterisation. Neuroscience 2002; 114: 1005-17.
- Femagut PO, Diguet E, Bioulac B, Tison F. MPTP potentiates 3-nitropropionic acid-induced striatal damage in mice: refer-ence to striatonigral degeneration. Exp Neurol 2004; 185: 47–62.
- Femagut PO, Chalon S, Diguet E, Guilloteau D, Tison F, Jaber M. Motor behaviour deficits and their histopathological and functional correlates in the nigrostriatal system of dopamine transporter knockout mice. Neuroscience 2003; 116: 1123–30.
- Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, Bates GP, et al. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 1999; 19: 3248–57.
- Diguet E, Femagut PO, Scherfler C, Wenning G, Tison F. Effects of riluzole on combined MPTP 3-nitropropionic acid induced mild to moderate striatonigral degeneration in mice. J Neural Transm 2005; 112: 613–31.
- Boyce S, Wyatt A, Webb JK, O'Donnell R, Mason G, Rigby M, et al. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisa-tion of NR2B subunit in dorsal horn. Neuropharmacology 1999; 38: 611–23.
- Landwehrmeyer GB, Dubois B, De Yebenes JG, Kremer B, Gaus W, Kraus PH, et al. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann Neurol 2007; 62: 262–72.